Advanced Search

 

Study ID Status Title Patient Level Data
FFR30007 Completed A 4 week randomized, double blind, placebo controlled study of GW685698X Aq nasal spray 100mcg QD in adults and adolescents with Vasomotor Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFR30008 Completed A two week randomized, double blind placebo controlled, parallel group study of GW685698X Aqueous Nasal Spray 100mcg and 50mcg QD in pediatric subjects with Perennial Allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU105924 Completed A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU105927 Completed A Randomized, Double-blind, Placebo-controlled, Active Comparator, One-Week, Cross-Over, Multicenter Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU108556 Completed A Patient Preference Evaluation Study of Fluticasone Furoate Nasal Spray and Fluticasone Propionate Aqueous Nasal Spray in Subject with Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU109045 Completed A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the Treatment of Seasonal Allergic Rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU109047 Completed A Comparison of Fluticasone Furoate Nasal Spray versus Oral Fexofenadine in the treatment of seasonal allergic rhinitis Study Listed on ClinicalStudyDataRequest.com
FFU111439 Completed A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 years of Age and Older with Perennial Allergic Rhinitis (PAR) Study Listed on ClinicalStudyDataRequest.com
Flu-Pan-Meta-Analysis-201109 Completed Integrated summary of the safety of AS03-adjuvanted monovalent H5N1 and H1N1 vaccines in adults 18 years of age and older
FMS40273 Completed A study to investigate the effect of inhaled fluticasone propionate on the bronchial responsiveness to leukotriene D4 in asthmatics patients
FRX106365 Completed A randomized, controlled trial to evaluate the effects of nadroparin on survival and disease progression in patients with advanced malignancies of the lung, pancreas, or prostate Study Listed on ClinicalStudyDataRequest.com
FTI102595 Withdrawn Dose ranging trial for the evaluation of the safety and efficacy of GW813893 in the prophylaxis of venous thromboembolism post total knee replacement surgery.
GLP105330 Completed A randomized, open-label, placebo-controlled, repeat-dose study to assess the pharmacokinetics and pharmacodynamics of 5 micrograms exenatide administered subcutaneously twice daily for 7 days in healthy normal volunteers and in subjects with Type 2 Diabetes Mellitus
GLP106073 Completed A single-blinded randomized, placebo-controlled, staggered-parallel, escalating-dose study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of subcutaneous injections of GSK 716155 in Subjects with type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
GLP107030 Completed A Single-Blind, Randomized, Placebo-Controlled Study in Healthy Men and Women to Determine the Effect of Single Subcutaneous Injections of GSK716155 on Gastric Emptying Time for Solid and Liquid Components of a Meal Study Listed on ClinicalStudyDataRequest.com
GLP107724 Completed An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy, Normal Volunteers Study Listed on ClinicalStudyDataRequest.com
GLP107865 Completed Clinical assessment of GSK716155 for Type 2 Diabetes Mellitus -A Phase I/II study to investigate the safety, pharmacokinetics and pharmacodynamics of GSK716155 in Japanese subjects with type 2 diabetes mellitus Study Listed on ClinicalStudyDataRequest.com
GLP110125 Completed A 16-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy, Safety, and Tolerability of Multiple Doses and Multiple Treatment Regimens of GSK716155, with Byetta as an Open Label Active Reference, in Subjects with Type 2 Diabetes Mellitus Study Listed on ClinicalStudyDataRequest.com
GRZ107460 Completed A Phase 2a, Multicenter, Randomized, Parallel, Double-Blind, Dose Ranging, Placebo-Controlled Study to Compare Antiviral Effect, Safety, Tolerability and Pharmacokinetics of GSK364735 Monotherapy Versus Placebo Over 10 days in HIV-1 Infected Adults.
GRZ108532 Completed A Single Dose, Randomized, 5-Period, Balanced, Crossover Study to Assess the Relative Bioavailability of Three Formulations and Food Effect on GSK364735 and Pharmacokinetics Following a Double Blind, Placebo Controlled, Repeat Dose Administration to Healthy Subjects.
GT1109727 Completed Single-Blind, randomised, placebo-controlled first time in human study to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of single oral escalating doses of GSK1018921 in healty volunteers and a randomized, double-blind, double dummy, placebo controlled, three-way crossover study in a separate cohort of healthy volunteers to test the effect of single doses of GSK1018921 and nicotine on qEEG and MMN in healthy volunteers
GW679769/903 Completed A Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Effects of GW679769 (30mg and 90mg) on Sleep Continuity, PSG Sleep Recordings, Subjective Sleep Assessment, and Daytime Cognitive Function in Subjects with Primary Insomnia
GW679769/904 Completed An exploratory study to investigate the effects of the NK1 antagonist GW679769, 60 mg once daily for 4 days, on gastric accommodation, gastric emptying and gastric distension-induced perception and discomfort in adult male and female patients with functional dyspepsia, in a single center, placebo-controlled, double-blind, randomised, two-period crossover study
H3A106104 Terminated An Open Label, Dose Escalation Study With A Double Blind Randomised Placebo Controlled Withdrawal To Examine The Effects Of The Histamine H3 Antagonist GSK189254 In Patients With Narcolepsy.
H3A106308 Completed A double-blind, double-dummy, placebo-controlled, incomplete block, two period crossover study of the histamine H3 antagonist GSK189254 and duloxetine in the electrical hyperalgesia model of central sensitisation in healthy volunteers

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.